Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This research is being done to test whether differences in blood cells at baseline (start of
the study) can be used to predict how well omalizumab will work in a patient. Omalizumab
(Xolair) is a drug approved by the U.S. Food and Drug Administration (FDA) to treat asthma.
Studies show that omalizumab improves the symptoms of asthma but some people experience
better improvement than others.